Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,947 public trials 2,015 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Recruiting

Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

NCT06471738

Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, +13 more
Locations: Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital Beijing, China

View Trial Details

Recruiting

A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT07558915

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Peter MacCallum Cancer Center Parkville, Victoria, Australia

View Trial Details

Recruiting

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

NCT06176690

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, +17 more
Locations: Houston Methodist Hospital Houston, Texas, United States

Texas Children's Hospital Houston, Texas, United States

View Trial Details

Recruiting

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations: Mitchell Cancer Institute Mobile, Alabama, United States

Arizona Oncology Associates, P.C. - HOPE Tucson, Arizona, United States

Cancer Specialists, LLC Jacksonville, Florida, United States

Minnesota Oncology Hematology, P.A. Coon Rapids, Minnesota, United States

View all 50 locations

View Trial Details

Recruiting

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

NCT06042725

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Recruiting

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

NCT07387926

Conditions: Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +11 more
Locations: Novartis Investigative Site Ramat Gan, Israel

View Trial Details

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: Research Site Huntsville, Alabama, United States

Research Site Anchorage, Alaska, United States

Research Site Phoenix, Arizona, United States

Research Site Clovis, California, United States

View all 224 locations

View Trial Details

Recruiting

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

NCT07046078

Conditions: Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Bone Marrow Diseases, +22 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

NCT07098364

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +20 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

NCT07082803

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations: Stanford Medicine Cancer Center Palo Alto, California, United States

The START Center for Cancer Care - Midwest Grand Rapids, Michigan, United States

Washington University School of Medicine St Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center New York, United States

View all 14 locations

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions